Skip to main content

Information updates

Updated ASCIA Adrenaline Injectors FAQ

ASCIA Adrenaline Injectors Frequently Asked Questions (FAQ) has been updated to provide more information about PBS and Pharmac listings of adrenaline injectors in Australia and New Zealand. The updated FAQ is available on the ASCIA website https://www.allergy.org.au/hp/anaphylaxis/adrenaline-injectors-faqs

The updated information is shown below in blue..

Q 1: What adrenaline injectors are available in Australia and New Zealand?

ASCIA recommends the use of adrenaline (epinephrine) as the first line emergency/first aid treatment for severe allergic reactions (anaphylaxis) using either of the following two brands of adrenaline injector devices:

  • EpiPen® - Available in Australia (PBS* listed since 2003) and New Zealand (Pharmac** listed since 2023).
  • Anapen® - Available in Australia (PBS listed since 2021).

*Australian Government Pharmaceutical Benefits Scheme (PBS)

The initial PBS authority prescription for up to two adrenaline injector devices can be provided to patients:
  • assessed to be at significant risk of anaphylaxis by a clinical immunology/allergy specialist, respiratory physician or a paediatrician, or by a GP in consultation with one of these specialists; or
  • after treatment with adrenaline for anaphylaxis when they are discharged from a hospital or emergency department.

A doctor (including a GP) or nurse practitioner can provide follow-up PBS authority prescriptions for replacement of devices just prior to expiry, or devices used for treatment of anaphylaxis.

**New Zealand Government Pharmaceutical Management Agency (Pharmac)

The initial Pharmac authority prescription for up to two adrenaline injector devices can be provided to patients:

  • assessed to be at significant risk of anaphylaxis by a relevant practitioner; or
  • who have experienced a previous anaphylactic reaction which has resulted in presentation to a hospital or emergency department.

Additional prescriptions are limited to replacement of devices just prior to expiry, or devices used for treatment of anaphylaxis. 

This news item was issued on 25 January 2024 by Jill Smith, CEO of ASCIA, the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand.